Ludwig Maximilians University, Munich - Friedrich Baur Institut
Welcome,         Profile    Billing    Logout  
 6 Trials 
15 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Schoser, Benedikt
NIMBLE, NCT05070858 / 2020-003272-41: A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis

Active, not recruiting
3
288
Europe, Canada, Japan, US, RoW
Pozelimab + Cemdisiran, Cemdisiran, ALN-CC5, Placebo, Pozelimab, REGN3918
Regeneron Pharmaceuticals
Generalized Myasthenia Gravis
07/25
11/28
REACH, NCT05397470 / 2022-000389-16: Efficacy and Safety of Losmapimod in Treating Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)

Terminated
3
260
Europe, Canada, US
Losmapimod, Placebo oral tablet
Fulcrum Therapeutics
Facioscapulohumeral Muscular Dystrophy (FSHD)
11/24
11/24
ACHIEVE, NCT05481879 / 2022-000889-18: Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-101 in Participants With Myotonic Dystrophy Type 1

Recruiting
1/2
116
Europe, US, RoW
DYNE-101, Placebo
Dyne Therapeutics, Dyne Therapeutics, Inc
Myotonic Dystrophy Type 1 (DM1)
07/29
07/29
EFES-BIO-SEP, NCT04767360: Effects of BIONESS in Rehabilitation of Stroke

Completed
N/A
32
Europe
Bioness-300
LMU Klinikum, Peter Young Neurological Clinic Medicalpark Bad Feilnbach, Germany
Stroke
10/21
12/22
NCT03458832: Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD

Recruiting
N/A
320
Europe, US
FSHD-specific functional rating scale, FSHD-COM, Electrical Impedance Myography, EIM
University of Kansas Medical Center, National Institute of Neurological Disorders and Stroke (NINDS), FSHD Society, Friends Research Institute, Inc., Muscular Dystrophy Association, AFM Telethon, University of Rochester, Leiden University Medical Center, Dyne Therapeutics
Facioscapulohumeral Muscular Dystrophy
06/27
12/27
NCT03981575: Estab Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1)

Recruiting
N/A
700
Europe, Canada, US, RoW
Virginia Commonwealth University, University of Rochester, Stanford University, Ohio State University, University of Florida, University of Iowa, Ludwig-Maximilians - University of Munich, Fondazione Serena Onlus - Centro Clinico NeMO Milano, The Methodist Hospital Research Institute, Radboud University Medical Center, University College London Hospitals, University of California, Los Angeles
Myotonic Dystrophy 1, DM1
10/26
12/26
Bassez, Guillaume
ACHIEVE, NCT05481879 / 2022-000889-18: Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-101 in Participants With Myotonic Dystrophy Type 1

Recruiting
1/2
116
Europe, US, RoW
DYNE-101, Placebo
Dyne Therapeutics, Dyne Therapeutics, Inc
Myotonic Dystrophy Type 1 (DM1)
07/29
07/29
SMA-AtHome, NCT05839145: Home Monitoring of Adult Patients With SMA: a Pilot Multicenter Validation Study

Not yet recruiting
N/A
60
Europe
Strength force measurment, MyoGrip/Pinch, Time tests, 10mWT, 30STS, 6MWT, 9HPT, Motor scales, Questionnaires, Accelerometry, MNR, Bio-impedance analysis
Institut de Myologie, France, Roche Pharma AG
Muscular Atrophy, Spinal, Type II, Muscular Atrophy, Spinal, Type III
01/24
01/24
NCT03981575: Estab Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1)

Recruiting
N/A
700
Europe, Canada, US, RoW
Virginia Commonwealth University, University of Rochester, Stanford University, Ohio State University, University of Florida, University of Iowa, Ludwig-Maximilians - University of Munich, Fondazione Serena Onlus - Centro Clinico NeMO Milano, The Methodist Hospital Research Institute, Radboud University Medical Center, University College London Hospitals, University of California, Los Angeles
Myotonic Dystrophy 1, DM1
10/26
12/26
NCT06078553: A Natural History Study in Participants With Congenital Myasthenic Syndromes (CMS) Due to Mutations in DOK7, MUSK, AGRN, or LRP4

Recruiting
N/A
100
Europe, Canada, US
argenx
Congenital Myasthenic Syndrome
06/27
06/27
ReSOLVE_France, NCT04038138: Clinical Trial Readiness Network FSHD France: Prospective 24 Months MRI Study

Completed
N/A
100
Europe
Validation of new COA for FSHD patients
Centre Hospitalier Universitaire de Nice
Muscular Dystrophy, Facioscapulohumeral
09/25
09/25
Jain, Gayatri
IBM-FRS, NCT04789070: Phase III Trial of Sirolimus in IBM

Active, not recruiting
3
140
US, RoW
Sirolimus, Rapamune, Placebo
University of Kansas Medical Center, The Perron Institute
Inclusion Body Myositis
12/26
12/26
ACHIEVE, NCT05481879 / 2022-000889-18: Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-101 in Participants With Myotonic Dystrophy Type 1

Recruiting
1/2
116
Europe, US, RoW
DYNE-101, Placebo
Dyne Therapeutics, Dyne Therapeutics, Inc
Myotonic Dystrophy Type 1 (DM1)
07/29
07/29
Mijic, Marko
ACHIEVE, NCT05481879 / 2022-000889-18: Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-101 in Participants With Myotonic Dystrophy Type 1

Recruiting
1/2
116
Europe, US, RoW
DYNE-101, Placebo
Dyne Therapeutics, Dyne Therapeutics, Inc
Myotonic Dystrophy Type 1 (DM1)
07/29
07/29
NCT05890833: The Risk of Falls Index for Patients With Neuromuscular Disorders

Completed
N/A
30
Europe
The risk of falls
LMU Klinikum
Inclusion Body Myositis, Myotonic Dystrophy, Facioscapulohumeral Muscular Dystrophies, Myasthenia Gravis, The Falls Efficacy Scale International, The Morse Fall Scale
09/24
09/24
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Schoser, Benedikt
NIMBLE, NCT05070858 / 2020-003272-41: A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis

Active, not recruiting
3
288
Europe, Canada, Japan, US, RoW
Pozelimab + Cemdisiran, Cemdisiran, ALN-CC5, Placebo, Pozelimab, REGN3918
Regeneron Pharmaceuticals
Generalized Myasthenia Gravis
07/25
11/28
REACH, NCT05397470 / 2022-000389-16: Efficacy and Safety of Losmapimod in Treating Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)

Terminated
3
260
Europe, Canada, US
Losmapimod, Placebo oral tablet
Fulcrum Therapeutics
Facioscapulohumeral Muscular Dystrophy (FSHD)
11/24
11/24
ACHIEVE, NCT05481879 / 2022-000889-18: Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-101 in Participants With Myotonic Dystrophy Type 1

Recruiting
1/2
116
Europe, US, RoW
DYNE-101, Placebo
Dyne Therapeutics, Dyne Therapeutics, Inc
Myotonic Dystrophy Type 1 (DM1)
07/29
07/29
EFES-BIO-SEP, NCT04767360: Effects of BIONESS in Rehabilitation of Stroke

Completed
N/A
32
Europe
Bioness-300
LMU Klinikum, Peter Young Neurological Clinic Medicalpark Bad Feilnbach, Germany
Stroke
10/21
12/22
NCT03458832: Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD

Recruiting
N/A
320
Europe, US
FSHD-specific functional rating scale, FSHD-COM, Electrical Impedance Myography, EIM
University of Kansas Medical Center, National Institute of Neurological Disorders and Stroke (NINDS), FSHD Society, Friends Research Institute, Inc., Muscular Dystrophy Association, AFM Telethon, University of Rochester, Leiden University Medical Center, Dyne Therapeutics
Facioscapulohumeral Muscular Dystrophy
06/27
12/27
NCT03981575: Estab Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1)

Recruiting
N/A
700
Europe, Canada, US, RoW
Virginia Commonwealth University, University of Rochester, Stanford University, Ohio State University, University of Florida, University of Iowa, Ludwig-Maximilians - University of Munich, Fondazione Serena Onlus - Centro Clinico NeMO Milano, The Methodist Hospital Research Institute, Radboud University Medical Center, University College London Hospitals, University of California, Los Angeles
Myotonic Dystrophy 1, DM1
10/26
12/26
Bassez, Guillaume
ACHIEVE, NCT05481879 / 2022-000889-18: Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-101 in Participants With Myotonic Dystrophy Type 1

Recruiting
1/2
116
Europe, US, RoW
DYNE-101, Placebo
Dyne Therapeutics, Dyne Therapeutics, Inc
Myotonic Dystrophy Type 1 (DM1)
07/29
07/29
SMA-AtHome, NCT05839145: Home Monitoring of Adult Patients With SMA: a Pilot Multicenter Validation Study

Not yet recruiting
N/A
60
Europe
Strength force measurment, MyoGrip/Pinch, Time tests, 10mWT, 30STS, 6MWT, 9HPT, Motor scales, Questionnaires, Accelerometry, MNR, Bio-impedance analysis
Institut de Myologie, France, Roche Pharma AG
Muscular Atrophy, Spinal, Type II, Muscular Atrophy, Spinal, Type III
01/24
01/24
NCT03981575: Estab Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1)

Recruiting
N/A
700
Europe, Canada, US, RoW
Virginia Commonwealth University, University of Rochester, Stanford University, Ohio State University, University of Florida, University of Iowa, Ludwig-Maximilians - University of Munich, Fondazione Serena Onlus - Centro Clinico NeMO Milano, The Methodist Hospital Research Institute, Radboud University Medical Center, University College London Hospitals, University of California, Los Angeles
Myotonic Dystrophy 1, DM1
10/26
12/26
NCT06078553: A Natural History Study in Participants With Congenital Myasthenic Syndromes (CMS) Due to Mutations in DOK7, MUSK, AGRN, or LRP4

Recruiting
N/A
100
Europe, Canada, US
argenx
Congenital Myasthenic Syndrome
06/27
06/27
ReSOLVE_France, NCT04038138: Clinical Trial Readiness Network FSHD France: Prospective 24 Months MRI Study

Completed
N/A
100
Europe
Validation of new COA for FSHD patients
Centre Hospitalier Universitaire de Nice
Muscular Dystrophy, Facioscapulohumeral
09/25
09/25
Jain, Gayatri
IBM-FRS, NCT04789070: Phase III Trial of Sirolimus in IBM

Active, not recruiting
3
140
US, RoW
Sirolimus, Rapamune, Placebo
University of Kansas Medical Center, The Perron Institute
Inclusion Body Myositis
12/26
12/26
ACHIEVE, NCT05481879 / 2022-000889-18: Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-101 in Participants With Myotonic Dystrophy Type 1

Recruiting
1/2
116
Europe, US, RoW
DYNE-101, Placebo
Dyne Therapeutics, Dyne Therapeutics, Inc
Myotonic Dystrophy Type 1 (DM1)
07/29
07/29
Mijic, Marko
ACHIEVE, NCT05481879 / 2022-000889-18: Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-101 in Participants With Myotonic Dystrophy Type 1

Recruiting
1/2
116
Europe, US, RoW
DYNE-101, Placebo
Dyne Therapeutics, Dyne Therapeutics, Inc
Myotonic Dystrophy Type 1 (DM1)
07/29
07/29
NCT05890833: The Risk of Falls Index for Patients With Neuromuscular Disorders

Completed
N/A
30
Europe
The risk of falls
LMU Klinikum
Inclusion Body Myositis, Myotonic Dystrophy, Facioscapulohumeral Muscular Dystrophies, Myasthenia Gravis, The Falls Efficacy Scale International, The Morse Fall Scale
09/24
09/24

Download Options